Clinical Trial Update: Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on exemestane as adjuvant therapy in postmenopausal women with non-metastatic breast cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 3 | Status: COMPLETED